Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 22Leukemia, Myeloid, Acute 21Breast Neoplasms 19Neoplasm Metastasis 16Pancreatic Neoplasms 15Multiple Myeloma 14Prostatic Neoplasms 12Melanoma 12Lymphoma 11Colorectal Neoplasms 11Carcinoma, Renal Cell 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 10Triple Negative Breast Neoplasms 9Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Mouth Neoplasms 8Glioma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Oropharyngeal Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Laryngeal Neoplasms 7Fallopian Tube Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Sarcoma 6Nasopharyngeal Carcinoma 6Endometrial Neoplasms 6

Interventions

remdesivir 1fludarabine 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Methods 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Autoimmune Diseases × Specimen Handling × 30 days × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡